CLU and Alzheimer disease: Using western-blot, we found that the expression of LRP-2 protein was found significantly different among three groups (F(2,25) = 41.90, p < 0.001), which increased in clusterin treating group when comparing to non-treat (p < 0.001) and saline group (p < 0.001) (Fig. 3c, d) in the post Turkey test, suggesting that LRP-2 protein was involved in the reduction of amyloid deposition after clusterin peptide treatment in AD transgenic mice.